UnitedHealth Group's Q1 2016 earnings call presented a strong enterprise-wide performance with significant revenue growth led by OptumRx and UnitedHealthcare. However, concerns around the individual exchange market, where the company significantly decreased participation and forecasted financial losses, might create short-term pressures. Despite this, improved performance across other segments, higher customer retention rates, and strategic focus on quality improvements suggest a buffer against any immediate reverses. Given the mixed signals but positive overarching performance, the stock is likely to experience a positive impact in the short term. 

[1]